[
    [
        {
            "time": "",
            "original_text": "医药生物行业周报：医药行业整体回调 关注超跌板块",
            "features": {
                "keywords": [
                    "医药",
                    "生物",
                    "行业周报",
                    "整体回调",
                    "超跌板块"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "医药生物行业周报：医药行业整体回调 关注超跌板块",
                "Correlation": 7,
                "Sentiment": 4,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "【异动股】药明康德(02359-HK)涨4.13%",
            "features": {
                "keywords": [
                    "药明康德",
                    "异动股",
                    "涨4.13%"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【异动股】药明康德(02359-HK)涨4.13%",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2016",
            "original_text": "药明巨诺是由药明康德和美国朱诺（Juno）在2016年合资成立，药明巨诺是「药明系三号」现于10月22日-28日招股。",
            "features": {
                "keywords": [
                    "药明巨诺",
                    "合资",
                    "药明康德",
                    "Juno",
                    "招股"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "药明巨诺是由药明康德和美国朱诺（Juno）在2016年合资成立，药明巨诺是「药明系三号」现于10月22日-28日招股。",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2017",
            "original_text": "过去药明生物是药明康德的子公司，但在2017年药明康德一拆为三，药明生物就是其中之一。药明生物的业务模式跟药明康德是非常类似的，都建立了药物研发的全产业链。但药明康德专注于做化学药，而药明生物只做生物药，两者毫无竞争关系。",
            "features": {
                "keywords": [
                    "药明生物",
                    "药明康德",
                    "拆分",
                    "化学药",
                    "生物药"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "过去药明生物是药明康德的子公司，但在2017年药明康德一拆为三，药明生物就是其中之一。药明生物的业务模式跟药明康德是非常类似的，都建立了药物研发的全产业链。但药明康德专注于做化学药，而药明生物只做生物药，两者毫无竞争关系。",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "医药CDMO子行业跟踪报告：十页带你读懂中国小分子创新药CDMO",
            "features": {
                "keywords": [
                    "医药",
                    "CDMO",
                    "子行业",
                    "创新药"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "医药CDMO子行业跟踪报告：十页带你读懂中国小分子创新药CDMO",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "生物医药行业深度报告：疫情、医保、集采 影响终端销售的三个关键词",
            "features": {
                "keywords": [
                    "生物医药",
                    "疫情",
                    "医保",
                    "集采",
                    "终端销售"
                ],
                "sentiment_score": -0.5,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "生物医药行业深度报告：疫情、医保、集采 影响终端销售的三个关键词",
                "Correlation": 6,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 6,
                "Duration": 9,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-10-27",
            "original_text": "港股盘前必读：蚂蚁集团H股发行价为80港元/股 发售时间为10月27日至30日",
            "features": {
                "keywords": [
                    "蚂蚁集团",
                    "H股",
                    "发行价",
                    "80港元",
                    "发售时间"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "金融科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "港股盘前必读：蚂蚁集团H股发行价为80港元/股 发售时间为10月27日至30日",
                "Correlation": 2,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 7,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]